As Congress continues to scrutinize the rising cost of insulin, two insulin producers and a pharmacy benefit manager (PBM) scrambled to put their best side in the spotlight. Read More
Cambridge, Mass.-based Inozyme Pharma Inc. just added $67 million to its financing with a series A2 boost led by Pivotal Bioventure Partners and Sofinnova Investments. Read More
VIENNA – Current FDA-approved options for patients infected with the hepatitis B virus (HBV) consist of immunomodulators, and nucleoside and nucleotide analogues, all of which target chronic disease and suppress virus replication, but do not cure HBV and leave no options for acute patients. Read More
HONG KONG – Commercial-stage biotech company Beigene Ltd. and clinical-stage company Bioatla LLC agreed to co-develop and bring to the market BA-3071, an investigational CAB CTLA4 antibody, as a monotherapy and in combination with Beigene's investigational anti-PD-1 antibody, tislelizumab, to treat cancer. Read More
DUBLIN – Avectas Ltd. raised $10 million in equity finance to fund the scale-up, validation and commercialization of its virus-free gene transfer technology. Read More
Azitra Inc., a Connecticut-based startup working on a bacteria-based therapy for the rare genetic skin condition Netherton syndrome (NS), has been awarded a $719,700 SBIR grant to advance development of its lead candidate, AZT-02. Read More
Phasebio Pharmaceuticals Inc., of Malvern, Pa., said it has begun an underwritten public offering of 3 million shares of its common stock and expects to grant the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock at the public offering price. Read More
A U.S. federal grand jury indicted Indivior Inc., formerly Reckitt Benckiser Pharmaceuticals Inc., and Indivior plc on one count of health care fraud, four counts of mail fraud and 22 counts of wire fraud related to the company's marketing of Suboxone Film (buprenorphine) as a treatment of opioid addiction. Read More
Alligator Bioscience AB, of Lund, Sweden, said preclinical data showed that ATOR-1015 physically localizes to the tumor in an experimental tumor model using a live imaging computerized technique. Alligator said the data, presented at the Essential Protein Engineering Summit in Boston, reinforce the concept that its wholly owned CTLA4 bispecific antibody selectively activates the immune system in the tumor area. Read More
Kaleido Biosciences Inc., of Lexington, Mass., appointed Johan van Hylckama Vlieg chief scientific officer and Clare Fisher chief business officer. Read More
